Axial Spondyloarthritis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Unknown stages are 2, 6, 1, 2 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Axial Spondyloarthritis - Overview
Axial Spondyloarthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Axial Spondyloarthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Axial Spondyloarthritis - Companies Involved in Therapeutics Development
AstraZeneca Plc
Eli Lilly and Company
Johnson & Johnson
Novartis AG
Panacea Biotec Ltd
Sandoz International GmbH
Sun Pharma Advanced Research Company Ltd
UCB SA
Axial Spondyloarthritis - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brodalumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixekizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
secukinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tildrakizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ustekinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Axial Spondyloarthritis - Dormant Projects
Axial Spondyloarthritis - Product Development Milestones
Featured News & Press Releases
Apr 24, 2017: Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA)
Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Erelzi
Mar 06, 2017: First CIMZIA Study of Its Kind Showed Minimal to No Transfer of Drug from Mother's Plasma to Breast Milk
Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting
Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS
Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)
Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting
Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting
Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis
Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study
Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis
Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting
Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting
Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Axial Spondyloarthritis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H1 2017
Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H1 2017
Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H1 2017
Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2017
Axial Spondyloarthritis - Pipeline by Panacea Biotec Ltd, H1 2017
Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2017
Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Axial Spondyloarthritis - Pipeline by UCB SA, H1 2017
Axial Spondyloarthritis - Dormant Projects, H1 2017